Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 74 | 92 | +18 |
| Shares | 20.1M | 21.4M | +1.38M (+6.9%) |
| Value | $252.1M | $387.3M | +$135.2M (+53.6%) |
New holders (26)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (8)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| TimesSquare Capital Management, LLC | 1,192,660 | $15.0M |
| Deerfield Management Company, L.P. (Series C) | 1,156,032 | $14.5M |
| Rubric Capital Management LP | 221,488 | $2.78M |
| Prelude Capital Management, LLC | 17,365 | $218.3K |
| Qube Research & Technologies Ltd | 10,352 | $130.1K |
| STRS Ohio | 3,800 | $47.0K |
| Aquatic Capital Management LLC | 400 | $5.00K |
| Massmutual Trust Co FSB | 95 | $1.19K |